12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Trastuzumab emtansine: Additional Phase III data

Additional data from the open-label, international Phase III EMILIA trial in 991 HER2-positive metastatic breast cancer patients showed that 3.6 mg/kg IV T-DM1 given every 3 weeks led to median OS, a co-primary endpoint, of 30.9 months vs. 25.1 months for Tykerb lapatinib plus Xeloda capecitabine (HR=0.68, p=0.0006). Roche and its Genentech unit previously reported that T-DM1 met the co-primary endpoints of PFS (9.6 vs. 6.4 months, HR=0.65, p<0.0001) and OS vs. Tykerb plus Xeloda (see BioCentury, April 2; June 11; & Sept. 3). On secondary endpoints, T-DM1 significantly improved ORR vs. Tykerb plus Xeloda (43.6% vs. 30.8%, p<0.001). There were 4 complete...

Read the full 511 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >